GlassScriptPhysician profile
Ashley Duke
NPI 1467894279
$3,765.88
in general payments reported to CMS, 2019-2025
25 companies · $685 in 2025
The $685 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $493 · 2023: $886 · 2024: $1,224 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.61 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $664.26 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.57 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $515.45 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $355.49 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $346.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.88 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $137.03 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $115.23 | 2022-2024 | |
| Exact Sciences Corporation | $106.09 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $102.25 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $85.77 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.99 | 2021-2022 | |
| Glaxosmithkline, LLC. | $72.42 | 2022-2025 | Bexsero, Shingrix, Arexvy |
| Astellas Pharma US INC | $63.35 | 2021 | |
| Abbvie INC. | $61.55 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.69 | 2021-2022 | |
| Sanofi Pasteur INC. | $58.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $49.38 | 2021-2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.94 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $19.85 | 2021 | |
| Hologic Sales and Service, LLC | $19.80 | 2023 | Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $18.25 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $15.13 | 2023 | Xarelto |
| Smith+Nephew, INC. | $14.97 | 2025 | Renasys Touch |
| Amgen INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.